For medical-technology and pharmaceuticals manufacturing, “the most effective answer is not tariffs but tax policy,” Johnson ...

Johnson & Johnson Chief Executive Joaquin Duato said on Tuesday that tariffs on pharmaceuticals can create supply chain ...

J&J’s comments and guidance update come as the company kicks off 2025’s first-quarter earnings round for large drugmakers.

With recession concerns circulating in the market, Johnson & Johnson (JNJ) stock could stabilize many portfolios. Since its founding in ...

Johnson & Johnson expects full-year earnings in the range of $10.50 to $10.70 per share, with revenue in the range of $91 billion to $91.8 billion. This story was generated by Automated Insights ( ...

"Trying to force your will to break the spirit of working people in order to have a conversation? That's terrorism. We're not ...

Healthcare and medical technology company Johnson & Johnson (JNJ) has reported first-quarter financial results that beat Wall Street ...